You are here
Home > Drugs > Diet and Irritable Bowel Syndrome (IBS)


Diet and Irritable Bowel Syndrome (IBS)

According to the American College of Gastroenterology, only a few
processes related to diet have been addressed in clinical trials such as
intolerance and hypersensitivity.  The findings so far have not been
conclusive and provide limited guidance on how dietary changes could be
used in the management of IBS.  Key findings include.3

  • Responses to particular foods and interactions with elements
    of the diet have not typically undergone rigorous evaluation.
  • True food allergies are uncommon in IBS
  • Most food-related IBS symptoms appear to represent food
    intolerance, however few patients can accurately locate the
    specific food.
  • The quality of evidence regarding specialized diets such as
    ‘gluten-free’ in reducing symptoms of IBS is very low. Although
    some of these diets show promise, the precise role in the
    management of IBS is unknown.

The role of fiber in IBS

Dietary fiber can be classified as either
soluble or insoluble. Soluble fiber dissolves in water and forms a gel.
It is found in several vegetables, fruits, and cereals. Insoluble fiber
does not not absorb or dissolve in water and passes through our
intestines largely intact.

Key points related to fiber: 3,8

  • Fiber can provide overall symptom relief in IBS.
    [Recommendation: weak. Quality of evidence:
    moderate. ]
  • Soluble fibers such as psyllium (not insoluble
    fibers such as bran) seem to provide overall symptom
  • Insoluble fibers are more likely to exacerbate
    IBS and may cause bloating and abdominal discomfort.

Check out our soluble fiber calculator:


Metamucil dosing info:

Based on information from the Metamucil website.
Accessed: July 2017.
© 2017 Procter & Gamble

  • Serving size amounts differ by version because the
    sweeteners and flavorings used in each Metamucil product
    vary in volume.
    Note: 1 teaspoon (sugar-free powder) = 1 tablespoon
    (sugar version).
  • Is it OK to take Metamucil with food? Should I take it
    before or after meals?
    Any time of day is
    appropriate to take Metamucil as long as an adequate
    intake of fluids (at least 8 ounces of water or
    liquid per serving) is consumed. We recommend taking
    Metamucil three times per day at mealtimes as a
    convenient way to get the benefits of Metamucil.
  • Bulk-forming fibers like psyllium husk, may affect how
    well medicines work. Take this product at least 2 hours
    before or after medicines.
  • Our powdered product must be mixed with liquids,
    not taken in its dry form. Capsules should be taken
    one at a time; we do not recommend dissolving them
    in water. Please take Metamucil with at least 8
    ounces of liquid, as indicated.
  • Metamucil cannot be added to hot beverages. 
    Rapid formation of gel.
  • New Users: Start with 1 serving per day;
    gradually increase to desired daily intake. You may
    initially experience changes in bowel habits or
    minor bloating, as your body adjusts to increased
    fiber intake.

Dosage:  [sugar-free version]
For promoting and maintaining digestive health:
Adults 12 yrs. and over: One rounded teaspoon in 8 oz.
of liquid up to 3 times daily for fiber supplementation.
For occasional constipation and to help promote and
maintain regularity. For children under 12, consult a

Note: 1 teaspoon (sugar-free powder) = 1 tablespoon
(sugar version).

Supplement information
Sugar-free version
1 rounded teaspoon: [5.8 grams of psyllium husk]
Dietary fiber: 3 grams
Soluble fiber: 2 grams

2 rounded tsp: [11.6 grams of psyllium husk]
Dietary fiber: 6 grams
Soluble fiber: 5 grams

Sugar (sucrose) version
1 rounded tablespoon:
Dietary fiber: 3 grams
Soluble fiber: 2 grams

2 rounded tbsp:
Dietary fiber: 6 grams
Soluble fiber: 5 grams

>>> Probiotics, prebiotics, and antibiotics


  1. Lovell RM , Ford AC . Global prevalence of, and risk
    factors for, irritable bowel syndrome: a meta-analysis . Clin Gastroenterol Hepatol 2012; 10 : 712 – 21 .
  2. Quigley EM , Abdel-Hamid H , Barbara G et al. A global
    perspective on irritable bowel syndrome: a consensus statement of the World
    Gastroenterology Organisation Summit Task Force on Irritable Bowel Syndrome . J Clin Gastroenterol 2012 ; 46 : 356 – 66 .
  3. Ford AC, et al.   American College of Gastroenterology monograph on
    the management of irritable bowel syndrome and chronic
    idiopathic constipation Am J Gastroenterol 2014 109 Suppl 1
    S2-S26. PubMed.
  4. Chang, L., Lembo, A., and Sultan, S. American
    Gastroenterological Association technical review on the
    pharmacological management of irritable bowel
    syndrome. Gastroenterology. 2014; 147: 1149-1172.
  5. Simren M,  Palsson OS,  Whitehead WE. Update on
    Rome IV Criteria for Colorectal Disorders: Implications for
    Clinical Practice.  Curr Gastroenterol Rep. 2017;
    19(4): 15.  Published online 2017 Apr 3. doi:
    10.1007/s11894-017-0554-0 PMCID: PMC5378729
  6. Drossman DA. Functional Gastrointestinal Disorders: History,
    Pathophysiology, Clinical Features and Rome IV.
    Gastroenterology. 2016;150:1262-1279.
  7. American Gastroenterological Association Institute Guideline
    on the Pharmacological Management of Irritable Bowel
    Syndrome. Accessed: July 2017. Available at:
  8. Zuckerman MJ. The role of fiber in the treatment of
    irritable bowel syndrome: therapeutic recommendations. J
    Clin Gastroenterol. 2006 Feb;40(2):104-8.
  9. LINZESS(R) package insert.  Allergan USA, Inc. Ironwood
    Pharmaceuticals, Inc. Irvine, CA 92612 Cambridge, MA, 02142. 
    Revised: 1/2017. Accessed: July 2017.
  10. Amitiza® (lubiprostone) package insert.  Takeda
    Pharmaceuticals America, Inc. Deerfield, IL 60015. 
    Revised: 9/2016.  Accessed: July 2017.  


National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.


The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer